Search Bar & Filters
Found 76 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the pharmacokinetic profiles, safety, and tolerability of two investigational drugs, IVL3004 and IVL4002, compared to Vivitrol Naltrexone Long-Acting Injectable. This phase 1, open-label study involves healthy adult male volunteers aged 18 to 55 years. The purpose is to explore how these drugs behave in the body when given as single ascending doses and to assess any safety concerns. The study consists of multiple groups receiving single doses of either Vivitrol via intramuscular injection or varying doses of IVL3004 and IVL4002 administered either intramuscularly or subcutaneously. Participants will receive these injections in a fixed sequence to compare the pharmacokinetic properties of each drug. Participants will undergo assessments from before dosing up to day 57, including measurements of drug concentration over time AUC and Cmax. They will be monitored for safety and tolerability through physical exams, laboratory tests, and observation for adverse effects. The total study participation spans several weeks with follow-up visits to collect data on how the drugs are processed in the body and any side effects experienced.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the WiSE CRT System combined with an intracardiac pacemaker to deliver completely leadless cardiac resynchronization therapy CRT for patients with heart failure. This study is a single-arm, prospective, multicenter, observational trial designed to assess this novel device system that provides left ventricular pacing along with right ventricular pacing for biventricular stimulation. Participants receive the WiSE CRT System implanted to provide left ventricular pacing in combination with an existing system that provides right ventricular pacing. Together, these devices deliver biventricular pacing to the heart. The study follows a single treatment group where WiSE System therapy is turned on alongside guideline-directed medical therapy. The trial collects data over a period that includes assessments at 1 month and 6 months after implantation. During the study, participants will be monitored for device and procedure-related complications, and evaluated with electrocardiograms to confirm biventricular capture at 1 and 6 months. Additional measures include changes in heart function such as ejection fraction and left ventricular volume, as well as improvements in heart failure symptoms and physical capacity using the New York Heart Association NYHA class and six-minute walk test at 6 months. The total participation duration extends up to 6 months, with safety and effectiveness closely observed throughout.
Actively Recruiting
Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.
Actively Recruiting
Researchers are conducting the BALANCE platform trial to study different treatment strategies for Gram-negative bloodstream infections GN BSIs. This adaptive trial addresses important questions about managing these infections, which have high risks and are complicated by increasing antibiotic resistance. The trial builds on previous research and aims to improve treatment approaches and patient outcomes while addressing antimicrobial resistance challenges. Participants in the trial receive various treatments depending on the domain they are assigned to. These include strategies such as antibiotic de-escalation or continuation, use of oral beta-lactams versus non-beta-lactams, decisions about replacing or retaining central vascular catheters, comparison of cephalosporins versus carbapenems for certain bacteria, and whether to perform routine follow-up blood cultures. The trial is open-label and embedded in routine hospital care, with an adaptive design that allows adding or removing treatment domains over time. During the study, participants undergo regular evaluations including monitoring for death, reinfection, readmission, and development of antimicrobial resistance over 90 days. The main measurement used is the Desirability of Outcome Ranking DOOR scale. Interim analyses occur frequently to assess results and determine continuation. Participation includes hospital admission, treatment under routine care with study interventions, and follow-up for outcome assessments. The study is planned to continue until April 2028 and enrolls patients from newborns to elderly adults.
Actively Recruiting
Researchers are conducting a phase II randomized placebo-controlled trial to study oral N-Acetylcysteine NAC in individuals who carry the Huntington disease gene but do not yet show clear motor symptoms. The study aims to assess clinical and brain imaging outcomes over a three-year period, focusing on slowing disease progression in this premanifest stage. Participants will be randomly assigned to take either 1 gram of NAC capsules or matching placebo capsules twice daily by mouth. The study is quadruple-masked, meaning that participants, caregivers, investigators, and outcome assessors do not know which treatment is assigned. The treatment period lasts up to three years, with ongoing monitoring throughout. During the study, participants will undergo regular brain MRI scans to measure caudate atrophy rate and be evaluated for motor changes indicating disease progression. Various cognitive and behavioral tests, such as the UHDRS motor subscale, Stroop Word test, and Montreal Cognitive Assessment, will be performed at intervals over the three years. Safety will be monitored through laboratory tests, ECGs, and tracking of adverse events. Participants must comply with study procedures including blood draws and MRI scans for the full duration up to the study end in May 2027.
Actively Recruiting
Researchers are evaluating denecimig Mim8 for adults diagnosed with acquired haemophilia A, a rare bleeding disorder. This Phase 3 open-label study aims to assess the safety and effectiveness of denecimig in reducing bleeding episodes in this population. The study is sponsored by Novo Nordisk AS and will follow participants for up to about one year and five months. Participants will receive subcutaneous injections of denecimig during the study. The treatment period includes a main part lasting 12 weeks followed by an extension phase up to 52 weeks. Denecimig plasma levels and the occurrence of antidrug antibodies will be monitored throughout the treatment. The study also tracks bleeding events and the use of other bleeding management therapies. During the study, participants will be closely monitored for treated and clinically relevant bleeding episodes, infections, and immune responses. The primary outcome is the number of treated bleeds during the first 12 weeks of treatment. Secondary outcomes include bleeding frequency, treatment days with bypassing agents or factor VIII products, and denecimig plasma concentration over one year. Participants are expected to follow study procedures and seek medical attention as needed during the approximately 73-week study period.
Actively Recruiting
Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.
Actively Recruiting
The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.
Actively Recruiting
Researchers are evaluating treatments for newly diagnosed multiple myeloma in patients who cannot undergo autologous stem cell transplantation. This Phase 3 study compares two drug combinations belantamab mafodotin with lenalidomide and dexamethasone BRd versus daratumumab with lenalidomide and dexamethasone DRd. The goal is to see if BRd extends progression-free survival and improves minimal residual disease negative status compared to DRd. Participants receive either BRd or DRd treatment, continuing until disease progression, death, unacceptable side effects, withdrawal, or study end. Both treatment arms involve the administration of lenalidomide and dexamethasone alongside either belantamab mafodotin or daratumumab. Treatment duration may last up to approximately seven years. During the study, participants will undergo regular assessments including monitoring disease progression, response to treatment, and side effects. Measurements include progression-free survival, overall survival, and the number achieving minimal residual disease negative status. Quality of life questionnaires and blood tests will also be conducted. Safety monitoring includes eye exams and tracking adverse events throughout the study duration.
Actively Recruiting
Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.
1-10 of 76
1